Pancreatic Cancer Research

Clinical trialPhase 3Completed

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

NCT02184195↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Outcome unknown
Phase
Phase 3
Status
Completed
Study type
Interventional
Start
16 December 2014
Expected end
27 January 2023
Enrollment
154 participants
Sites
103
Primary outcomes
Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1)
Sponsor
Industry
Results posted
2020-01-27
Last update
13 September 2023

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 8